In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. All scholarly work records and full-texts stored in Manchester eScholar were migrated to the new system prior to this transition. From August 2016 the University’s research outputs will be available to view and download via the new Research Portal. Until then the old eScholar content WILL BE TEMPORARILY available to search and browse via this archive.

Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis

Heald, A; Selby, P L; White, A; Gibson, J M

American Journal of Obstetrics and Gynecology. 2000;183(3):593-600.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally

Abstract

OBJECTIVE: We sought to investigate the effect of oral progestins on estrogen-mediated changes in the insulin-like growth factor axis in the peripheral circulation. STUDY DESIGN: Oral conjugated equine estrogen alone or in combination with medroxyprogesterone acetate, desogestrel, or norethindrone was given in a randomized triple-crossover fashion to 10 healthy postmenopausal women, and the effects on the insulin-like growth factor axis were determined. RESULTS: Baseline circulating insulin-like growth factor I levels were significantly reduced by conjugated equine estrogen (359 +/- 54 vs 225 +/- 44 ng/mL; P = .0001). This effect was reversed by progestins (medroxyprogesterone acetate, 254 +/- 44 ng/mL; desogestrel, 266 +/- 50 ng/mL; norethindrone, 286 +/- 48 ng/mL; F = 12.2; P = .0015). Free insulin-like growth factor I was reduced by conjugated equine estrogen (1.00 +/- 0.15 ng/mL vs 2.10 +/- 0.39 ng/mL; P = .004), but addition of progestogens had no further effect. Insulin-like growth factor II and insulin levels were unaffected by conjugated equine estrogen or progestins. Plasma insulin-like growth factor binding protein 1 concentration increased significantly from baseline with conjugated equine estrogen alone (44.1 +/- 6.0 vs 154 +/- 30 mu g/L; P = .003). This rise was opposed by progestins of increasing androgenicity (medroxyprogesterone acetate, 130 +/- 26 mu g/L; desogestrel, 100 +/- 16 mu g/L; norethindrone, 78.0 +/- 12 mu g/L; F = 12.5; P = .0015). Insulin-like growth factor binding protein 3 levels fell with conjugated equine estrogen, and this was reversed by progestins (conjugated equine estrogen, 2.17 +/- 0.13 mg/L; vs norethindrone and conjugated equine estrogen, 2.41 +/- 0.12 mg/L; F = 7.6; P = .01). Insulin-like growth factor binding protein 4 levels increased with conjugated equine estrogen with or without progestins, whereas insulin-like growth factor binding protein 2 levels were unchanged. CONCLUSIONS: Coadministration of androgenic progestins abrogates estrogen-related changes in circulating insulin-like growth factor I, insulin-like growth factor binding protein 1, and insulin-like growth factor binding protein 3. Such hormone replacement therapy-induced changes may have significant consequences for the development of cardiovascular disease and osteoporosis and implications for the use of insulin-like growth factor I in monitoring growth hormone replacement.

Bibliographic metadata

Type of resource:
Content type:
Published date:
ISSN:
Volume:
183
Issue:
3
Start page:
593
End page:
600
Total:
8
Pagination:
593-600
ISI Accession Number:
ISI:000089407200012
Related website(s):
  • Related website <Go to ISI>://000089407200012
Access state:
Active

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:151220
Created by:
Gibson, Martin
Created:
15th January, 2012, 15:04:08
Last modified by:
Gibson, Martin
Last modified:
1st February, 2013, 19:46:41

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.